Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

Imagem de Miniatura
Arquivos
art_ATAGA_Crizanlizumab_for_the_Prevention_of_Pain_Crises_in_2017.PDF (505.16 KB)
Citações na Scopus
498
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MASSACHUSETTS MEDICAL SOC
Autores
ATAGA, K. I.
KUTLAR, A.
KANTER, J.
LILES, D.
CANCADO, R.
FRIEDRISCH, J.
GUTHRIE, T. H.
KNIGHT-MADDEN, J.
ALVAREZ, O. A.
GORDEUK, V. R.
Citação
NEW ENGLAND JOURNAL OF MEDICINE, v.376, n.5, p.429-439, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell-cell interactions that are involved in the pathogenesis of vaso-occlusion and sickle cell-related pain crises. The safety and efficacy of crizanlizumab, an antibody against the adhesion molecule P-selectin, were evaluated in patients with sickle cell disease. METHODS In this double-blind, randomized, placebo-controlled, phase 2 trial, we assigned patients to receive low-dose crizanlizumab (2.5 mg per kilogram of body weight), high-dose crizanlizumab (5.0 mg per kilogram), or placebo, administered intravenously 14 times over a period of 52 weeks. Patients who were receiving concomitant hydroxyurea as well as those not receiving hydroxyurea were included in the study. The primary end point was the annual rate of sickle cell-related pain crises with high-dose crizanlizumab versus placebo. The annual rate of days hospitalized, the times to first and second crises, annual rates of uncomplicated crises (defined as crises other than the acute chest syndrome, hepatic sequestration, splenic sequestration, or priapism) and the acute chest syndrome, and patient-reported outcomes were also assessed. RESULTS A total of 198 patients underwent randomization at 60 sites. The median rate of crises per year was 1.63 with high-dose crizanlizumab versus 2.98 with placebo (indicating a 45.3% lower rate with high-dose crizanlizumab, P = 0.01). The median time to the first crisis was significantly longer with high-dose crizanlizumab than with placebo (4.07 vs. 1.38 months, P = 0.001), as was the median time to the second crisis (10.32 vs. 5.09 months, P = 0.02). The median rate of uncomplicated crises per year was 1.08 with high-dose crizanlizumab, as compared with 2.91 with placebo (indicating a 62.9% lower rate with high-dose crizanlizumab, P = 0.02). Adverse events that occurred in 10% or more of the patients in either active-treatment group and at a frequency that was at least twice as high as that in the placebo group were arthralgia, diarrhea, pruritus, vomiting, and chest pain. CONCLUSIONS In patients with sickle cell disease, crizanlizumab therapy resulted in a significantly lower rate of sickle cell-related pain crises than placebo and was associated with a low incidence of adverse events.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/19944
Referências
  1. Ataga KI, 2011, BRIT J HAEMATOL, V153, P92, DOI 10.1111/j.1365-2141.2010.08520.x
  2. Ballas SK, 2012, BLOOD, V120, P3647, DOI 10.1182/blood-2012-04-383430
  3. Ballas SK, 2005, AM J HEMATOL, V79, P17, DOI 10.1002/ajh.20336
  4. Bunn HF, 1997, NEW ENGL J MED, V337, P762
  5. Candrilli SD, 2011, AM J HEMATOL, V86, P273, DOI 10.1002/ajh.21968
  6. Chang CH, 2010, STROKE, V41, P1884, DOI 10.1161/STROKEAHA.110.585828
  7. CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001
  8. Chuang SY, 2015, STROKE, V46, P996, DOI 10.1161/STROKEAHA.114.007932
  9. Embury SH, 2004, BLOOD, V104, P3378, DOI 10.1182/blood-2004-02-0713
  10. Frenette PS, 2004, MICROCIRCULATION, V11, P167, DOI 10.1080/10739680490278556
  11. Gutsaeva DR, 2011, BLOOD, V117, P727, DOI 10.1182/blood-2010-05-285718
  12. HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803
  13. Heeney MM, 2016, NEW ENGL J MED, V374, P625, DOI 10.1056/NEJMoa1512021
  14. Kutlar A, 2012, AM J HEMATOL, V87, P536, DOI 10.1002/ajh.23147
  15. LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D
  16. Manwani D, 2013, BLOOD, V122, P3892, DOI 10.1182/blood-2013-05-498311
  17. Matsui NM, 2002, BLOOD, V100, P3790, DOI 10.1182/blood-2002-02-0626
  18. Matsui NM, 2001, BLOOD, V98, P1955, DOI 10.1182/blood.V98.6.1955
  19. PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303
  20. Polanowska-Grabowska R, 2010, ARTERIOSCL THROM VAS, V30, P2392, DOI 10.1161/ATVBAHA.110.211615
  21. Rees DC, 2010, LANCET, V376, P2018, DOI 10.1016/S0140-6736(10)61029-X
  22. Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001/jama.289.13.1645
  23. Turhan A, 2002, P NATL ACAD SCI USA, V99, P3047, DOI 10.1073/pnas.052522799
  24. van Tuijn CFJ, 2010, AM J HEMATOL, V85, P532, DOI 10.1002/ajh.21731
  25. Wun T, 1997, J LAB CLIN MED, V129, P507, DOI 10.1016/S0022-2143(97)90005-6
  26. Zarbock A, 2007, BLOOD REV, V21, P99, DOI 10.1016/j.blre.2006.06.001

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC